Composite Scoring System and Optimal Tumor Budding Cut-Off Number for Estimating Lymph Node Metastasis in Submucosal Colorectal Cancer

Jeong-ki Kim
Chung-Ang University Hospital

Ye-Young Rhee
Seegene Medical Foundation

Jeong Mo Bae
Seoul National University College of Medicine

Jung Ho Kim
Seoul National University College of Medicine

Seong-Joon Koh
Seoul National University College of Medicine

Hyun Jung Lee
Seoul National University College of Medicine

Jong Pil Im
Seoul National University College of Medicine

Min Jung Kim
Seoul National University College of Medicine

Seung-Bum Ryoo
Seoul National University College of Medicine

Seung-Yong Jeong
Seoul National University College of Medicine

Kyu Joo Park
Seoul National University College of Medicine

Ji Won Park (✉ sowisdom@gmail.com)
Seoul National University College of Medicine

Gyeong Hoon Kang
Seoul National University College of Medicine

Research Article

Keywords: Colorectal neoplasm, Histopathology, Lymph nodes metastasis, Tumor budding
Abstract

Background
Tumor budding is associated with lymph node (LN) metastasis in submucosal colorectal cancer (CRC). However, the rate of LN metastasis associated with the number of tumor buds is unknown. Here, we determined the optimal tumor budding cut-off number and developed a composite scoring system (CSS) for estimating LN metastasis of submucosal CRC.

Methods
In total, 395 patients with histologically confirmed T1N0–2M0 CRC were evaluated. The clinicopathological characteristics were subjected to univariate and multivariate analyses. The Akaike information criterion (AIC) values of the multivariate models were evaluated to identify the optimal cut-off number. A CSS for LN metastasis was developed using independent risk factors.

Results
The prevalence of LN metastasis was 13.2%. Histological differentiation, lymphatic or venous invasion, and tumor budding were associated with LN metastasis in univariate analyses. In multivariate models adjusted for histological differentiation and lymphatic or venous invasion, the AIC value was lowest for five tumor buds. Unfavorable differentiation (odds ratio [OR], 8.16; 95% confidence interval [CI], 1.80–36.89), lymphatic or venous invasion (OR, 5.91; 95% CI, 2.91–11.97), and five or more tumor buds (OR, 3.01; 95% CI, 1.21–7.69) were independent risk factors. In a CSS using these three risk factors, the rates of LN metastasis were 5.6%, 15.5%, 31.0%, and 52.4% for total composite scores of 0, 1, 2, and ≥ 3, respectively.

Conclusions
For the estimation of LN metastasis in submucosal CRC, the optimal tumor budding cut-off number was five. Our CSS can be utilized to estimate LN metastasis.

Introduction
Colorectal cancer (CRC) is a major cause of cancer-associated mortality and is the most common cancer worldwide (1). CRC can be cured by surgical treatment if detected early (stage I) without additional chemotherapy (2). Early CRC is increasingly detected by CRC screening. In early CRC cases, malignant polyps without deep invasion can be treated via endoscopic resection. Further radical surgery may be needed according to the probability of lymph node (LN) metastasis. The identification of risk factors for LN metastasis can assist in formulating a treatment strategy.
The prevalence of LN metastasis in submucosal CRC is 0–17.3% (3). The risk factors for LN metastasis in submucosal CRC include histopathological features, such as lymphatic or venous invasion (4–7), poorly differentiated carcinoma (8, 9), deep submucosal invasion (9, 10, 11), and tumor budding (4–6, 12). In addition, tumor volume, morphological features, mode of growth, absence of background adenoma, and/or lymphoid infiltration are histopathological factors associated with LN metastasis (8, 9, 13, 14). Tumor budding is defined as isolated single cells or clusters of up to four cells at the invasive margin (15). Tumor budding is an adverse factor in CRC (16–20). Furthermore, tumor budding is a predictive parameter for LN metastasis according to the guidelines of the European Society for Medical Oncology (21) and the Japanese Society for Cancer of the Colon and Rectum (22). To our knowledge, few studies have evaluated the optimal point of tumor budding for estimating LN metastasis in submucosal CRC. Here, we determined the optimal tumor budding cut-off number and developed a scoring system to estimate LN metastasis of submucosal CRC.

Materials And Methods

Study design and ethics

This was retrospective study determined the optimal tumor budding cut-off number and developed a scoring system to estimate LN metastasis of submucosal CRC. This study was reviewed and approved by the Institutional Review Board of the Seoul National University Hospital Biomedical Research Institute (approval number: H-2107-045-1232). All patients provided written informed consent and approval were obtained from all patients. All procedures were carried out in accordance with the relevant guidelines and regulations.

Patients

In total, 12,749 patients underwent surgery for CRC at Seoul National University Hospital from January 1, 2002, to December 31, 2019. Among them, patients who underwent a radical operation for submucosal CRC and had available histopathological reports were eligible for this study. Submucosal CRC was defined as an adenocarcinoma that invaded the submucosal layer and conformed to the classification guidelines of the American Joint Committee on Cancer Staging. Patients who received neoadjuvant therapy or underwent local resection were excluded. Finally, 395 patients were enrolled.

Data collection and pathological review

Data concerning patients’ clinicopathological parameters were collected from the electronic medical records. Sex, age, body mass index, American Society of Anesthesiologists score, carcinoembryonic antigen level, and tumor location were analyzed as clinical characteristics. Right colon cancer was defined as tumors in the cecum, ascending colon, and transverse colon; left colon cancer was defined as cancers in the descending and sigmoid colon; and rectal cancer was defined as tumors in the recto-sigmoid junction and the rectum (23).
Pathological features assessed were tumor histological type, lymphatic or venous invasion, perineural invasion, number of tumor buds, distance from the proximal to the distal margin, number of harvested LNs, and number of metastasized LNs. Tumors were histologically classified as favorable differentiation (well or moderately differentiated carcinoma) or unfavorable differentiation (poorly differentiated, undifferentiated, signet ring cell, or mucinous carcinoma), in accordance with the World Health Organization guidelines. Lymphatic or venous invasion was considered present when tumor cells invaded non-muscle-walled small vessels or large vessels with a smooth muscle layer and/or an elastic lamina layer (Fig. 1) (24). Perineural invasion was considered present when tumor cells reached the peripheral nerve sheath layers. To objectively evaluate tumor budding, we confirmed the existence of isolated single cells or clusters of up to four cells via hematoxylin and eosin staining of tumor tissues; the number of tumor budding in a microscopic field was verified at \( \times 200 \) magnification (Fig. 2). Pathological slides were assessed by three experienced gastrointestinal pathologists. The assessment of tumor budding was performed by another pathologist.

**Statistical analysis**

The clinical characteristics and pathological features were compared according to LN metastasis status to identify risk factors for LN metastasis. Pearson’s \( \chi^2 \) test or Fisher’s exact test was used to compare categorical variables; Student’s \( t \)-test was used to compare continuous variables. Multivariate logistic regression analysis was performed to identify independent risk factors that were predictive of LN metastasis. To identify the optimal tumor budding cut-off number, the sum of sensitivity and specificity for LN metastasis was established. The cut-off number was determined using the Akaike information criterion (AIC) from the adjusted multivariate models. The tumor budding cut-off values, from 0 to 12 at intervals of 1, were assessed as an indicator of LN metastasis based on the AIC. The best model exhibited the lowest AIC value. A composite scoring system (CSS) was developed to estimate LN metastasis by adding rounded values of the coefficients of independent risk factors. All statistical analyses were performed using SPSS 22 software (IBM Corp., Armonk, NY, USA). A \( p \)-value < 0.05 was considered statistically significant.

**Results**

The prevalence of LN metastasis was 13.2% (52/395). No clinical characteristics significantly differed between patients with and without LN metastasis (Table 1). Correlations between LN metastasis and pathological features are shown in Table 1. Tumors with LN metastasis had a higher prevalence of unfavorable differentiation (\( p = 0.022 \)) and lymphatic or venous invasion (\( p < 0.001 \)). The number of buds was higher in tumors with LN metastasis than in tumors without LN metastasis (\( p = 0.001 \)).
Table 1
Univariate analysis of Lymph node (LN) metastasis.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>LN (-), n = 343</th>
<th>LN (+), n = 52</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y) a</td>
<td>Mean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>62.3 ± 11.0</td>
<td>63.2 ± 10.5</td>
<td>0.581</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>225 (65.6%)</td>
<td>30 (57.7%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>118 (34.4%)</td>
<td>22 (42.3%)</td>
</tr>
<tr>
<td>BMI a</td>
<td>Mean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>23.9 ± 2.9</td>
<td>23.7 ± 2.95</td>
<td>0.628</td>
</tr>
<tr>
<td>ASA grade*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>107 (31.2%)</td>
<td>15 (28.8%)</td>
<td>0.957</td>
</tr>
<tr>
<td>II</td>
<td>218 (63.6%)</td>
<td>34 (65.5%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>14 (4.1%)</td>
<td>2 (3.8%)</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>4 (1.1%)</td>
<td>1 (1.9%)</td>
<td></td>
</tr>
<tr>
<td>CEA a</td>
<td>Mean</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>1.9 ± 2.5</td>
<td>2.1 ± 2.4</td>
<td>0.637</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>80 (23.3%)</td>
<td>10 (19.2%)</td>
<td>0.320</td>
</tr>
<tr>
<td>Left colon</td>
<td>153 (44.6%)</td>
<td>21 (40.4%)</td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td>109 (31.8%)</td>
<td>20 (38.5%)</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>1 (0.3%)</td>
<td>1 (1.9%)</td>
<td></td>
</tr>
<tr>
<td>Histologic type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favorable</td>
<td>321 (98.5%)</td>
<td>46 (92.0%)</td>
<td>0.022</td>
</tr>
<tr>
<td>Unfavorable</td>
<td>5 (1.5%)</td>
<td>4 (8.0%)</td>
<td></td>
</tr>
<tr>
<td>Lymphatic or venous invasion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>304 (88.6%)</td>
<td>28 (53.8%)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Positive</td>
<td>36 (10.5%)</td>
<td>21 (40.4%)</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>3 (0.9%)</td>
<td>3 (5.8%)</td>
<td></td>
</tr>
<tr>
<td>Perineural invasion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>324 (94.5%)</td>
<td>48 (92.3%)</td>
<td>1.000</td>
</tr>
<tr>
<td>Positive</td>
<td>2 (0.5%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>unknown</td>
<td>17 (5.0%)</td>
<td>4 (7.7%)</td>
<td></td>
</tr>
<tr>
<td>Tumor budding (n)a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 ± 3.6</td>
<td>4.0 ± 4.1</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)a</td>
<td>1.97±2.50</td>
<td>2.35±2.82</td>
<td>0.058</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologist; CEA, carcinoembryonic antigen

a. Mean ± standard error of the mean (SEM)
Table 2
Multivariate analysis of Lymph node (LN) metastasis.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histological type (unfavorable vs. favorable)</td>
<td>8.16</td>
<td>1.80–36.89</td>
<td>0.006</td>
</tr>
<tr>
<td>Lymphatic or venous invasion (positive vs. negative)</td>
<td>5.91</td>
<td>2.91–11.97</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Tumor budding (≥ 5 vs. &lt; 5/HPF)</td>
<td>3.01</td>
<td>1.21–7.69</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Figure 3 shows the prevalence of LN metastasis and the tumor budding value. The prevalence of LN metastasis in tumors with five tumor buds was 28.6%. Tumors with five or more buds had higher rates of LN metastasis than did tumors with fewer than five tumor buds. The highest summed sensitivity and specificity values for LN metastasis were 2 and 5, respectively (1.24 and 1.23, respectively). The cut-off number was determined using the AIC from the tumor budding logistic regression models, adjusted for histological type and lymphatic or venous invasion. The AIC value was lowest (246.8) for tumors with five buds (Fig. 4). Thus, the optimal tumor budding cut-off number was five.

In a multivariate analysis using a cut-off of five, unfavorable differentiation (odds ratio [OR], 8.16; 95% confidence interval [CI], 1.80–36.89; p = 0.006), positive lymphatic or venous invasion (OR, 5.91; 95% CI, 2.91–11.97; p < 0.001), and tumor budding (≥ 5/high-power field [HPF]; OR, 3.01; 95% CI, 1.21–7.69; p = 0.002) were significant predictive parameters for LN metastasis (Table 2). In the multivariate model, the coefficients for histological type, lymphatic or venous invasion, and tumor budding were 2.10, 1.78, and 1.10, respectively. By adding rounded coefficients, a composite score was developed (2 × histological type [favorable differentiation, 0; unfavorable differentiation, 1] + 2 × lymphatic or venous invasion [negative, 0; positive, 1] + 1 × tumor budding [< 5/HPF, 0; ≥ 5/HPF, 1]). Higher composite scores were associated with higher rates of LN metastasis (5.6%, 15.5%, 31.0%, and 52.4% for total composite scores of 0, 1, 2, and ≥ 3, respectively; Fig. 5).
Discussion

For the estimation of LN metastasis in submucosal CRC, the optimal tumor budding cut-off number was five. Imai reported that tumor budding or sprouting reflects faster tumor growth (25). In 1989, tumor budding was defined by Morodomi as a cluster of five or more cells that sprouted from tumor cells, regardless of tubular structure status (26). In addition, to determine the degree of budding, a pathological tissue slide was divided into four areas with dimensions of 500 × 2,500 µm, and the mean number of buds per area was calculated (25). The Japanese classification defines a tumor budding as an isolated single cell or cluster of cells consisting of fewer than five cells at the invasive margin of a tumor (27). In the present study, buds were enumerated using a 10× ocular lens at 20× magnification, in accordance with the Japanese classification. The tumor budding grade according to the number of buds in a 0.785-mm² field was defined as follows: grade 1, 0–4; grade 2, 5–9; and grade 3, ≥ 10 (27). A multicenter study by the Budding Investigation Project Committee of the Japanese Society for Cancer of the Colon and Rectum, in which grade 1 was defined as low grade and grade 2/3 was defined as high grade, showed that a high grade was associated with LN metastasis (27). When LN metastasis status was verified according to the number of tumor budding, the OR for five or more buds was 8.0 (26). In the present study, the rate of LN metastasis increased as the number of tumor buds increased. The AIC value was lowest with five tumor buds; thus, five was the optimal cut-off value, consistent with the definition of low grade in the Japanese classification. The presence of five or more buds was independently associated with LN metastasis.

The histopathological predictors of LN metastasis in submucosal CRC were the depth of invasion (submucosal invasion ≥ 1,000 µm), unfavorable differentiation (poorly differentiated, mucinous carcinoma, or signet-ring cell carcinoma), and lymphatic or venous invasion. We confirmed that unfavorable differentiation and lymphatic or venous invasion were independent predictors in a multivariate analysis. Ryu et al. reported that lymphatic invasion and histopathological differentiation were significant risk factors in 179 patients with early CRC (28). In a meta-analysis, lymphatic invasion was the most important predictor of LN metastasis; histological grade was also a key predictor (29). The European Society for Medical Oncology, Japanese Society for Cancer of the Colon and Rectum, National Comprehensive Cancer Network, and Korean clinical practice guidelines recommend additional radical operations after endoscopic resection of submucosal cancer in patients with an unfavorable histological grade, deep submucosal invasion, lymphatic or venous invasion, or tumor budding (21, 22, 30, 31). A limitation of the present study was that it did not confirm the depth of invasion. However, a population-based cohort study demonstrated that age < 60 years, mucinous carcinoma, lymphovascular invasion, and perineural invasion were independent predictive factors, whereas deep submucosal invasion was not significant in the multivariate analysis (p = 0.075), for patients with submucosal CRC undergoing a radical operation (32).

The prevalence of LN metastasis is 10–15% in patients who undergo additional operations after endoscopic resection (32–34). In our study, the prevalence of LN metastasis was 13.2%. Most patients without LN metastasis are at risk of surgical complications. To avoid unnecessary radical surgery and
failure to identify LN metastasis, a more precise predictive model for LN metastasis is needed. Several prediction models for LN metastasis in submucosal CRC have been developed (35–37). The least absolute shrinkage and selection operator prediction model includes histopathological factors (35); nomograms that included independent clinicopathological factors have also been used to estimate LN metastasis (36, 37). These predictive models have good discriminatory power. We developed a simple prediction scoring system for LN metastasis that can be applied in daily clinical practice. The relative risk of LN metastasis increased as the total composite score increased. Patients with a total composite score ≥ 2 had a LN metastasis rate > 30%. Additional surgery is recommended for these patients.

To our knowledge, this is one of few studies to investigate the optimal tumor budding cut-off number. However, our study was conducted in a single institution; some variables, including depth of invasion, were not fully available because of the retrospective design. A prospective, multi-center study is needed to obtain more accurate and detailed results.

**Conclusions**

For the estimation of LN metastasis in submucosal CRC, the optimal tumor budding cut-off number was five. Our CSS can be utilized to estimate LN metastasis.

**Abbreviations**

AIC: Akaike information criteria

ASA: American Society of Anesthesiologists

BMI: Body mass index

CEA: carcinoembryonic antigen

CI: confidence interval

CRC: Colorectal cancer

CSS: composite scoring system

HPF: high-power field

LN: lymph node

OR: odds ratio

**Declarations**

**Ethics approval and consent to participate**
This study was reviewed and approved by the Institutional Review Board of the Seoul National University Hospital Biomedical Research Institute (approval number: H-2107-045-1232). Informed consent was obtained from all patients. All procedures were carried out in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to ethical restrictions but are available from the corresponding author on reasonable request.

Competing interest

The authors declare that there is no conflict of interest.

Funding

This work was supported by the Korean government (MSIT) Grant No. 2021R1F1A1063000 from the National Research Foundation of Korea (NRF).

Authors’ contributions

JKK and YYR wrote the manuscript. SJK, HJL, JPI, JMB and JHK performed some of the lab work and data collection. MJK, SBR, SYJ and KJP supported the overall data analysis and provided constructive discussion. JKK, YYR, GHK and JWP conceived and designed the study. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Authors’ information

Jeong-ki Kim and Ye-Young Rhee contributed equally to this work.

Affiliations

Department of Surgery, Chung-Ang University Hospital, Seoul 06973, Republic of Korea

Chung-Ang University College of Medicine, Seoul 06973, Republic of Korea

Jeong-ki Kim
References


**Figures**

![Image](image.jpg)

**Figure 1**

Representative histopathological image of lymphatic or venous invasion (hematoxylin and eosin staining, x200).
Figure 2

Representative histopathological image of tumor budding, isolated single cells, or clusters of up to four cells (hematoxylin and eosin staining, ×200).
Figure 3

The prevalence of lymph node (LN) metastasis is associated with the number of tumor budding.
Figure 4

Akaike information criterion (AIC) in logistic regression models adjusted for histological type and lymphatic or venous invasion.
Figure 5

Prevalence of lymph node (LN) metastasis according to the total composite score. Total composite score: $2 \times$ histological type [favorable differentiation, 0; unfavorable differentiation, 1] $+ 2 \times$ lymphatic or venous invasion [negative, 0; positive, 1] $+ 1 \times$ tumor budding [$< 5$/HPF, 0; $\geq 5$/HPF, 1]